In an interview with Targeted Oncology, Yuqin Song, MD, PhD, discussed golidocitinib as the first JAK1 inhibitor developed for patients with T-cell lymphomas in this pivotal study.
Interviews
Advertisement
In an interview with Targeted Oncology, Bruno Bastos, MD, discussed how TPST-1120 can help address limited treatment options for patients with advanced renal cell carcinoma beyond immunotherapy and anti-VEGF tyrosine kinase inhibitors.
Advertisement
In an interview with Targeted Oncology, Sanjay Goel, MD, MS, discussed the mystery of cachexia in pancreatic cancer and why it remains a challenging symptom to target.
In an interview with Targeted Oncology, Stephen Williams, MD, discussed a retrospective cohort study presented at ASCO GU analyzing intravesical gemcitabine usage vs Bacillus Calmette-Guérin for the treatment of high-risk non-muscle invasive bladder cancer.
In an interview with Targeted Oncology, Guenther Koehne, MD, discussed the latest research surrounding autologous and allogeneic stem cell transplants.
In the second article of a 2-part series, Yara Abdou, MD, provided a deep dive into the evolving landscape of HER2-targeted therapy and its potential to revolutionize cancer treatment.
Advertisement
In an interview with Targeted Oncology, Geoffrey D. Moorer, MD, discussed recent trending topics in the field of oncology among hospital tumor boards and committees.
In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the first-in-human, phase 1/2 study of DSP-5336 in patients with relapsed or refractory acute myeloid leukemia.
In an interview with Targeted Oncology, Thomas Powles, MD, MBBS, MRCP, discussed the impressive performance of enfortumab vedotin plus pembrolizumab for the treatment of locally advanced or metastatic urothelial carcinoma, as seen in the EV-302 trial.
Matthew Matasar, MD, discussed the rationale and findings of the doublet consisting of ibrutinib and venetoclax for the treatment of mantle cell lymphoma.
Advertisement
In an interview with Targeted Oncology, Mark Dybul, MD, discussed a breakthrough method of immunotherapy in solid tumors.
In an interview with Targeted Oncology, Randeep Sangha, MD, discussed the background of the phase 1 study and the rationale for studying zelenirstat for the treatment of solid tumors and hematologic malignancies.
In the first article of a 2-part series, Yara Abdou, MD, discussed the most significant challenges and transformative advancements in the treatment of HER2-positive breast cancer.
In an interview with Targeted Oncology, Charu Aggarwal, MD, MPH, discussed the real-world study evaluating the link between molecular genotyping and survival among patients with non–small-cell lung cancer.
In an interview with Targeted Oncology, Jie Jin, MD, discussed the need for a standard therapy in peripheral T-cell lymphoma and highlighted the potential impact of the JACKPOT26 study.
In an interview with Targeted Oncology, Guenther Koehne, MD, provides a comprehensive overview of the dynamic landscape and evolving strategies in immunotherapy for hematologic malignancies.
In an interview with Targeted Oncology, Louise Morrell, MD, discussed the landscape of genetic testing in oncology and the latest advancements in the field.
In an interview with Targeted Oncology, Amer Assal, MD, provided insights into the risks and complications associated with stem cell transplants, emphasizing the importance of risk stratification and preventive measures.
Matthew J. Frigault, MD, MS, discussed follow-up data on the efficacy and safety of CART-ddBCMA for the treatment of patients with relapsed/refractory multiple myeloma, particularly in later-line settings.
In an interview with Targeted Oncology, Jon E. Arnason, MD, discussed an analysis looking at circulating tumor DNA among patients with follicular lymphoma and diffuse large B-cell lymphoma from the ELM-2 trial.
In an interview with Targeted Oncology, Naomi Dempsey, MD, provided insight into the benefits of endocrine therapy in patients with breast cancer and the implications of findings from this research.
David J. Andorsky, MD, discussed real-world findings from a study which evaluated BTK inhibitors in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
In an interview with Targeted Oncology, Jonathan W. Riess, MD, discussed the ever-changing EGFR-mutated lung cancer treatment landscape, highlighting several agents that are currently under development.
In an interview with Targeted Oncology, Lee Greenberger, PhD, discussed some of the latest, interesting research that caught his attention in 2023 and what community oncologists should know about the space as we move into 2024.
Haifa Kathrin Al-Ali, MD, discussed findings from the phase 1/2 CA011-023 study of BMS-986158 combined with ruxolitinib or fedratinib in myelofibrosis.
In an interview with Targeted Oncology, Ann LaCasce, MD, MMSc, delved into the surge of innovations with personalized medicine, advanced technologies, and novel agents for the treatment of patients with lymphomas.
In an interview with Targeted Oncology, Andre Goy, MD, discussed the potential of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory mantle cell lymphoma and how 2 studies provide support for use of the agent in this patient population.
In an interview with Targeted Oncology, Francis P. Worden, MD, shed light on the evolving landscape of advanced thyroid cancer treatment, offering valuable insights into the available options.
In an interview with Targeted Oncology, James Zou, PhD, provided an overview of AI and machine learning applications in oncology.
In an interview with Targeted Oncology, Jennifer A. Woyach, MD, discussed updated results from the phase 1/2 BRUIN study of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma following treatment with a covalent Bruton tyrosine kinase inhibitor.